title: A noradrenergic and serotonergic hypothesis of the linkage between epilepsy and affective disorders.
abstract: Noradrenergic and/or serotonergic deficits, as well as other abnormalities, may contribute to predisposition to some epilepsies and depressions. Evidence for this hypothesis stems from several sources. Epidemiological investigations are intriguing but incomplete. Pharmacological studies show that noradrenergic and/or serotonergic transmission are both anticonvulsant and antidepressant. Therapeutically pertinent investigations show that antidepressant drugs have anticonvulsant properties, whereas antiepileptic drugs are effective in the management of affective disorders. Additional investigations demonstrate that seizures, whether spontaneously occurring or therapeutically induced, protect against depression. Through studies of innate pathophysiology, noradrenergic and serotonergic deficits have been identified in individuals with depression and in animal models of epilepsy, as well as in some humans with epilepsy. Vagal nerve stimulation, a treatment already known to be effective in the epilepsies, is presently under investigation for effectiveness in affective disorder. New evidence suggests that vagal nerve stimulation exerts at least some of its therapeutic effects through its capacity to increase noradrenergic and serotonergic transmission. Finally, emerging evidence supports the concept that some genetic mammalian models of the human epilepsies exhibit analogous manifestations of depression.
authors.affiliation: Department of Biomedical and Therapeutic Sciences, University of Illinois College of Medicine-Peoria, 61656, USA.
authors.forename: P C
authors.initials: PC
authors.lastname: Jobe
authors.forename: J W
authors.initials: JW
authors.lastname: Dailey
authors.forename: J F
authors.initials: JF
authors.lastname: Wernicke
mesh_terms: D000818:Animals; D000927:Anticonvulsants / Q000627:therapeutic use; D000928:Antidepressive Agents / Q000627:therapeutic use; D001923:Brain Chemistry / Q000187:drug effects* / Q000502:physiology*; D015984:Causality; D003863:Depression / Q000150:complications* / Q000188:drug therapy / Q000209:etiology* / Q000503:physiopathology; D004195:Disease Models, Animal; D004599:Electric Stimulation Therapy / Q000639:trends; D004827:Epilepsy / Q000150:complications* / Q000188:drug therapy / Q000209:etiology* / Q000503:physiopathology; D006801:Humans; D008125:Locus Coeruleus / Q000166:cytology / Q000378:metabolism; D008959:Models, Neurological; D009638:Norepinephrine / Q000172:deficiency*; D051381:Rats; D012640:Seizures / Q000503:physiopathology; D012701:Serotonin / Q000172:deficiency*; D009435:Synaptic Transmission / Q000187:drug effects* / Q000502:physiology*; D014630:Vagus Nerve / Q000502:physiology; D005680:gamma-Aminobutyric Acid / Q000378:metabolism
chemical_list: D000927:Anticonvulsants; D000928:Antidepressive Agents; D012701:Serotonin; D005680:gamma-Aminobutyric Acid; D009638:Norepinephrine